enGene Therapeutics Inc. (ENGNW)
NCM
$2.23
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Exchange
NCM
Currency
USD
About enGene Therapeutics Inc.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Quarterly Financials
| Metric | 2025-04-30 | 2025-07-31 | 2025-10-31 | 2026-01-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.1M | -29.9M | -39.5M | -31.2M |
| Net Income | -25.8M | -29.0M | -37.9M | -29.8M |
Annual Financials
| Metric | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -19.4M | -26.1M | -62.3M | -123.2M |
| Net Income | -24.5M | -99.9M | -55.1M | -117.3M |